Testosterone for Androgen Deficiency-Like Symptoms in Men Without Pathologic Hypogonadism: A Randomized, Placebo-Controlled Cross-over With Masked Choice Extension Clinical Trial. (19th August 2019)

• Record Type: Journal Article
• Authors: Mok, Shao Feng; Fennell, Carolyn; Savkovic, Sasha; Turner, Leo; Jayadev, Veena; Conway, Ann; Handelsman, David J
• Editors: Newman, Anne
• Is Part Of: Journals of gerontology. Volume 75:Number 9(2020)
• Page Start: 1723
• Page End: 1731
• Publication Date: 2019-08-19
• Subjects: Testosterone -- Symptoms -- Quality of life -- Energy -- Sexual function; Geriatrics -- Periodicals; Gerontology -- Periodicals; 618.97
• DOI: 10.1093/gerona/glz195
• Languages: English
• ISSNs: 1079-5006

Abstract

Abstract: Background: Off-label testosterone prescribing for androgen deficiency (AD)-like sexual and energy symptoms of older men without pathologic hypogonadism has increased dramatically without convincing evidence of efficacy. Methods: In a randomized, double-blind, placebo-controlled study with three phases, we entered 45 men aged at least 40 years without pathologic hypogonadism but with AD-like energy and/or sexual symptoms to either daily testosterone or placebo gel treatment for 6 weeks in a cross-over study design with a third, mandatory extension phase in which participants chose which previous treatment they preferred to repeat while remaining masked to their original treatment. Primary endpoints were energy and sexual symptoms as assessed by a visual analog scale (Lead Symptom Score [LSS]). Results: Increasing serum testosterone to the healthy young male range produced no significant benefit more than placebo for energy or sexual LSS. Covariate effects of age, body mass index, and pretreatment baseline serum testosterone on quality-of-life scales were detected. Only 1 out of 22 indices from seven quality-of-life scales was significantly improved by testosterone treatment over placebo. Participants did not choose testosterone significantly more than placebo as their preferred treatment in the third phase. Conclusions: Six-week testosterone treatment does not improve energy or sexual symptoms more than placebo in symptomatic men without pathologic hypogonadism.